Cargando…
Glitazone Treatment Rescues Phenotypic Deficits in a Fly Model of Gaucher/Parkinson’s Disease
Parkinson’s Disease (PD) is the most common movement disorder, and the strongest genetic risk factor for PD is mutations in the glucocerebrosidase gene (GBA). Mutations in GBA also lead to the development of Gaucher Disease (GD), the most common type of lysosomal storage disorder. Current therapeuti...
Autores principales: | Shola-Dare, Oluwanifemi, Bailess, Shelby, Flores, Carlos C., Vanderheyden, William M., Gerstner, Jason R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657993/ https://www.ncbi.nlm.nih.gov/pubmed/34884544 http://dx.doi.org/10.3390/ijms222312740 |
Ejemplares similares
-
Glitazone use associated with reduced risk of Parkinson's disease
por: Brakedal, Brage, et al.
Publicado: (2017) -
Fabp7 Is Required for Normal Sleep Suppression and Anxiety-Associated Phenotype following Single-Prolonged Stress in Mice
por: Vanderheyden, William M., et al.
Publicado: (2022) -
Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study
por: Brauer, Ruth, et al.
Publicado: (2015) -
Are the adverse effects of glitazones linked to induced testosterone deficiency?
por: Carruthers, M, et al.
Publicado: (2008) -
Pleiotropic Effects of Glitazones: A Double Edge Sword?
por: Salomone, Salvatore
Publicado: (2011)